Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Saw Record Growth In 2008 Across Key Businesses

This article was originally published in The Pink Sheet Daily

Executive Summary

In contrast to Big Pharma’s doldrums, generics manufacturer Teva had a banner year in 2008 – and expects a strong follow up in 2009.

You may also be interested in...



Teva Continues To Position Itself For Overseas Opportunities

The world economic crisis favors generics, as it puts additional pressure on governments already struggling to contain health care spending and reduce other costs, Teva Pharmaceutical CEO Shlomo Yanai told investors on an earnings call Feb. 17

Teva Continues To Position Itself For Overseas Opportunities

The world economic crisis favors generics, as it puts additional pressure on governments already struggling to contain health care spending and reduce other costs, Teva Pharmaceutical CEO Shlomo Yanai told investors on an earnings call Feb. 17

Generic Drugs Don’t Come Cheap: Teva Buys Barr For $7.46 Billion

Teva's $7.46 billion acquisition of Barr will create an unrivaled generics powerhouse and position the company as a leader in the industry's next untapped frontier: biosimilars

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel